GH Research PLC
GHRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855129
No open-market purchases or sales by GH Research PLC insiders were filed in the last 90 days; 63 institutions reported holding it in 13F filings for Q2 2026, worth $1.38B in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding GH Research PLC changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 32 | 28 | −4 |
| Shares | 29.6M | 30.4M | +827.5K (+2.8%) |
| Value | $315.5M | $354.8M | +$39.2M (+12.4%) |
New holders (2)
Institutions that held GH Research PLC at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Alps Advisors Inc | 40,573 | $473.1K | 0.00% |
| Caption Management, LLC | 1,127 | $13.1K | 0.00% |
Sold out (6)
Institutions that held GH Research PLC at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Checkpoint Capital L.P. | 185,653 | $1.98M |
| Millennium Management LLC | 51,807 | $552.3K |
| Corton Capital Inc. | 15,526 | $165.5K |
| Susquehanna International Group, LLP | 10,542 | $112.4K |
| UBS Group AG | 209 | $2.23K |
| Qube Research & Technologies Ltd | 109 | $1.16K |